STAT

Social connections first, science second: How biotech’s recipe for success has its limits

The pivotal financial decisions that determine which biotech companies will survive and which will fail are determined largely by social capital — not by science.

When Laura Indolfi set out to launch a biotech in Boston, she had an idea — and little else. She had never run a company before. She had no practical experience in fundraising.

But she was undeterred. In 2014 she founded PanTher Therapeutics, with the goal of turning a postdoctoral side project into a bona-fide drug delivery company.

“I took a leap of faith,” she told STAT.

Through her five-year odyssey, Indolfi learned a fundamental lesson about the biotech world: who you know can be as important — or even more important — as what you want to do.

First, her “leap of faith’’ needed to be backed up with data. But soon, she needed to match it with cold, hard cash. She met with as many venture capitalists as she could fit into her schedule, hoping to find a

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT1 min read
STAT+: In Large Trial, Guardant Health’s Blood Test Detects Colon Cancer, But Less Reliably At Earliest Or Precancerous Stages
If approved, Guardant Health’s liquid biopsy is likely to be a strong new addition to colorectal cancer screening tools, particularly for patients who currently choose not to get screened.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.

Related Books & Audiobooks